Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review
T Wang, Y Li, X Zheng - BMC Health Services Research, 2023 - Springer
Background The combination of immunotherapy and chemotherapy for extensive-stage
small-cell lung cancer (ES-SCLC) was primarily carried out with a combination of immune …
small-cell lung cancer (ES-SCLC) was primarily carried out with a combination of immune …
Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis …
Background Serplulimab is a potential valuable therapy, while patients, physicians, and
decision-makers are uncertain about the cost-effectiveness of this novel drug and its …
decision-makers are uncertain about the cost-effectiveness of this novel drug and its …
circPVT1 and PVT1/AKT3 show a role in cell proliferation, apoptosis, and tumor subtype‐definition in small cell lung cancer
D Tolomeo, D Traversa, S Venuto… - Genes …, 2023 - Wiley Online Library
Small cell lung cancer (SCLC) is treated as a homogeneous disease, although the
expression of NEUROD1, ASCL1, POU2F3, and YAP1 identifies distinct molecular subtypes …
expression of NEUROD1, ASCL1, POU2F3, and YAP1 identifies distinct molecular subtypes …
Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a cost-effectiveness analysis
Y Zhu, K Liu, Q Qin, H Zhu - Frontiers in immunology, 2023 - frontiersin.org
Introduction The ASTRUM-005 trial (NCT04063163) revealed that combination serplulimab
plus chemotherapy (etoposide and carboplatin EC) treatment was associated with survival …
plus chemotherapy (etoposide and carboplatin EC) treatment was associated with survival …
Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
Z Ye, Z Xu, H Li, Q Li - Frontiers in Public Health, 2023 - frontiersin.org
Objective The TOPAZ-1 trial reported a significant survival benefit of durvalumab in
combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC) …
combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC) …
Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: A …
Y Gan, F Shi, H Zhu, S Han, D Li - Frontiers in Pharmacology, 2023 - frontiersin.org
Purpose: The aim of this study was to evaluate the cost-effectiveness of a recently approved
first-line therapy (adebrelimab plus chemotherapy vs. chemotherapy alone) for patients with …
first-line therapy (adebrelimab plus chemotherapy vs. chemotherapy alone) for patients with …
Bioorthogonal Diels–Alder Click Chemistry-Based Pretargeted PET Imaging Strategy for Monitoring Programmed Death-Ligand 1 Expression
Y Huang, Z Li, C Li, Z Zang, Q Wang, S Huang… - ACS …, 2024 - ACS Publications
The development of antibody tracers for positron emission tomography (PET) imaging
enables real-time monitoring of tumor expression of programmed cell death ligand 1 (PD …
enables real-time monitoring of tumor expression of programmed cell death ligand 1 (PD …
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive …
PC Hsu, BC Wu, CC Wang, LC Chiu, CH Chang… - Vaccines, 2024 - mdpi.com
Real-world clinical experience of using anti-programmed death-ligand 1 (PD-L1) immune
checkpoint inhibitors (ICIs) combined with chemotherapy in the first-line treatment of …
checkpoint inhibitors (ICIs) combined with chemotherapy in the first-line treatment of …
Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer
Z Zheng, H Chen, H Cai - Frontiers in Oncology, 2024 - frontiersin.org
Background Serplulimab has shown promising results in the treatment of extensive-stage
small cell lung cancer (ES-SCLC). This study aimed to evaluate the cost-effectiveness of …
small cell lung cancer (ES-SCLC). This study aimed to evaluate the cost-effectiveness of …
First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
Z Zheng, L Fang, H Cai - BMJ open, 2023 - bmjopen.bmj.com
Objective The objective of this study was to evaluate the cost-effectiveness of durvalumab in
combination with chemotherapy compared with chemotherapy alone as first-line therapy for …
combination with chemotherapy compared with chemotherapy alone as first-line therapy for …